Matthew Zuga
2023
In 2023, Matthew Zuga earned a total compensation of $1.6M as Chief Financial Officer and Chief Business Officer at Acumen Pharmaceuticals, a 35% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $234,131 |
|---|---|
| Option Awards | $699,003 |
| Salary | $450,253 |
| Stock Awards | $204,685 |
| Other | $18,217 |
| Total | $1,606,289 |
Zuga received $699K in option awards, accounting for 44% of the total pay in 2023.
Zuga also received $234.1K in non-equity incentive plan, $450.3K in salary, $204.7K in stock awards and $18.2K in other compensation.
Rankings
In 2023, Matthew Zuga's compensation ranked 701st out of 2,647 executives tracked by ExecPay. In other words, Zuga earned more than 73.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 701 out of 2,647 | 74th |
Division Manufacturing | 405 out of 1,447 | 72nd |
Major group Chemicals And Allied Products | 277 out of 817 | 66th |
Industry group Drugs | 271 out of 783 | 65th |
Industry Biological Products, Except Diagnostic Substances | 89 out of 204 | 56th |
Source: SEC filing on April 22, 2024.
Zuga's colleagues
We found two more compensation records of executives who worked with Matthew Zuga at Acumen Pharmaceuticals in 2023.